Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 EXECUTIVE SUMMARY - HARROW HEALTH, INC. | f8k052113_ex99z1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2013
IMPRIMIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
| 001-35814 |
| 45-0567010 |
|
|
|
|
|
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
|
|
|
12626 High Bluff Drive, Suite 150 |
| 92130 |
San Diego, CA |
|
|
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (858) 704-4040
N/A |
(Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
. |
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
. |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
. |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
. |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure
Attached as Exhibit 99.1 to this Item 7.01 is an executive summary that is being used by the management of Imprimis Pharmaceuticals, Inc. (the “Company") in meetings describing the Company.
The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
(d)
Exhibits
99.1
Executive Summary dated May 2013
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMPRIMIS PHARMACEUTICALS, INC.
Dated: May 21, 2013
By:
/s/ Mark L. Baum
Name: Mark L. Baum
Title: Chief Executive Officer
EXHIBIT INDEX
99.1
Presentation dated May 2013